Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dibrompropamidine→

Dibrompropamidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
496-00-4
Molecular formula
C17H18Br2N4O2
Molecular weight
470.2 g/mol
Drug class
Diamidine antiseptictopical antibacterial agent
Mechanism of action
Exerts local antimicrobial activity through interaction with microbial nucleic acids and cellular structures; the precise mechanism in ocular pathogens is not fully characterised.
Indications / reported uses
  • Topical ophthalmic treatment of superficial bacterial eye infections such as conjunctivitis and blepharitis in countries where dibrompropamidine isetionate products are authorised

Sources: NHS — Propamidine and dibrompropamidine eye products · NLM MeSH — Dibrompropamidine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dibrompropamidine Environmental Risk Assessment (ERA) (the Dibrompropamidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.